<DOC>
	<DOCNO>NCT02582632</DOCNO>
	<brief_summary>This study evaluate safety efficacy ombitasvir/paritaprevir/ ritonavir dasabuvir administer 8 week treatment-naïve participant genotype 1b hepatitis C virus ( HCV ) .</brief_summary>
	<brief_title>A Study Evaluate Ombitasvir/Paritaprevir/Ritonavir Dasabuvir Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Chronic HCV infection Screening . 2 . Screening laboratory result indicate HCV genotype 1b infection . 3 . Treatmentnaïve noncirrhotic . 1 . HCV genotype subtype GT1b . 2 . Positive test result Hepatitis B surface antigen ( HbsAg ) confirm positive antiHIV antibody ( HIV Ab ) ( test ) . 3 . Any current past clinical evidence cirrhosis . 4 . Screening laboratory analysis show abnormal result . 5 . Clinically significant abnormality comorbidities , HCV infection make participant unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Ribavirin-Free</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C Genotype 1b</keyword>
</DOC>